Hansoh Pharmaceutical is making a multifront push into siRNA. Days after disclosing a siRNA pact with OliX Pharmaceuticals, the Chinese biopharma powerhouse has unveiled a separate alliance with Silence Therapeutics. The latest deal sees Hansoh pay $16 million upfront and commit up to $1.3 billion in milestones for the chance to work with Silence. In return for the outlay, Hansoh has secured the option to license rights to two targets in greater China and pick up global rights to a third target. Source: Fierce Biotech 15/10/2021